A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16 ecto directed chimeric antigen receptors for recurrent ovarian cancer

Mythili Koneru,Roisin E. O’Cearbhaill,Swati Pendharkar,David R. Spriggs,Renier J. Brentjens

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16 ecto directed chimeric antigen receptors for recurrent ovarian cancer

2015

Mythili Koneru
Roisin E. O’Cearbhaill
Swati Pendharkar
David R. Spriggs
Renier J. Brentjens

Purpose Recurrent platinum-resistant ovarian cancer has no curative options, necessitating the development of novel treatments, including immunotherapy.

Keywords:

Chimeric antigen receptor
Ovarian cancer
Phases of clinical research
Tumor microenvironment
Immunology
Immunotherapy
Membrane protein
T cell
Interleukin 12
Medicine
Cancer
Antigen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

159

Citations